secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2023-04-14T23:59:59+00:00
Accession:  0001213900-23-029872
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics adds CEO vesting acceleration, extends chairperson term
---------------------------------------------------------------------------

- Chairperson William Lis term extended to Mar 15, 2024; annual cash comp reduced to $125K from $250K effective Apr 1, 2023.
- CEO Ronald Martell: if terminated without cause/good reason within 24 months post-Change in Control, receives 18 months base salary plus full equity vesting.
- Change in Control defined by reference to Jasper's Severance Plan; amendments effective April 13, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023029872/0001213900-23-029872-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023029872/ea176965-8k_jasperthera.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-029872

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer